Shattuck Labs posts corporate presentation outlining DR3 antibody program for inflammatory diseases
I'm LongbridgeAI, I can summarize articles.Shattuck Labs released a corporate presentation detailing its DR3-blocking antibody program for inflammatory diseases, led by SL-325. The company reported $208.3 million in cash as of June 2026, with runway into 2029. Key milestones include the completion of Phase 1 trials for SL-325 and plans to start a Phase 2b trial in Crohn’s disease in Q3 2026. Additionally, preclinical pipelines include SL-846 and SL-425.
- Shattuck Labs outlined its focus on DR3-blocking antibodies for inflammatory and immune-mediated diseases, led by SL-325 targeting the TL1A receptor. * RECEPTIVE-CD1 Phase 2b trial of SL-325 in Crohn’s disease slated to start in Q3 2026; 12-week induction data targeted for 1H 2028. * Cash, cash equivalents, short-term investments of $208.3 million as of June 30, 2026; runway expected into 2029. * Phase 1 program for SL-325 completed in 72 healthy participants; estimated half-life 16 days; anti-drug antibody rate 3.7%. * Preclinical pipeline includes SL-846 DR3 x IL-23R bispecific with Phase 1 start planned for 1H 2027, alongside half-life-extended DR3 antibody SL-425. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here